secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001193125-23-225486
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics to acquire Acer Therapeutics in stock-and-CVR merger
-----------------------------------------------------------------------

- Acer stockholders receive 0.120 Zevra shares per share plus one CVR; Zevra to issue ~2.96M shares.
- CVR milestones include up to $34M tied to OLPRUVA net sales, plus payments for FDA approvals of OLPRUVA and EDSIVO.
- Zevra provides $10M initial bridge loan at 12% to Acer; total facility up to $16.5M.
- Zevra purchases Acer debt from Nantahala: ~$20.2M SWK loans and ~$15.1M Marathon convertible notes.
- Acer pays $3M termination fee if it accepts superior proposal or breaches non-solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312523225486/0001193125-23-225486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312523225486/d547103d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-225486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer